| Sep 20 |
Fortress Biotech to sell 3.9M shares at $1.65 in registered direct offering
|
| Sep 20 |
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
|
| Sep 16 |
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
|
| Sep 9 |
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
|
| Sep 4 |
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 4 |
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 4 |
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Fortress Biotech GAAP EPS of -$0.73 beats by $0.49, revenue of $14.9M beats by $0.13M
|
| Aug 13 |
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 13 |
Fortress Biotech: Q2 Earnings Snapshot
|
